Gensco Pharma® Acquires Global Rights and IP for RizaFilm® and RizaPort®

Gensco Pharma acquires global rights to RizaFilm® and RizaPort®, with a U.S. migraine treatment launch planned for Q4 2025 and global expansion ahead.